Wutah pendapatan taun lumaku: Coherus Biosciences (CHRS)

Logo perusahaan publik coherus.com (CHRS)

Coherus Biosciences is implementing environmental standards to minimize the impact of chemical synthesis and reduce its carbon footprint. The year-over-year relative revenue growth rate (12 months) confirms the business dynamics, where the current parameter equals -35.30. The company relies on production outsourcing via CMOs, while the expansion of biosimilars and AI solutions strengthens its position on insurance formularies.

Coherus Biosciences (CHRS): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Coherus Biosciences - rincian analitis lan metrik utama (CHRS)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Coherus BioSciences Inc.
Produk merek Coherus BioSciences, Inc

The commercialization of Coherus Biosciences (CHRS) biosimilars in the US is protected by the humanitarian status of medicine, which minimizes geopolitical risks to operational activities. The annual revenue growth rate over the trailing four quarters measures the dynamics of sales expansion, allowing investors to identify early signs of revenue contraction and assess business resilience to market shocks via TTM trend analysis prior to the publication of official financial statements.

Karo sapa Coherus Biosciences saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur